Archives
Acifran: A Hypolipidemic Agent for Lipid Metabolism Research
Acifran: Driving Precision in Lipid Metabolism Regulation Research
Principle Overview: Acifran and Lipid Signaling Pathway Modulation
Acifran (SKU B6848), chemically identified as (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, is a selective agonist for the HM74A/GPR109A and GPR109B receptors—key members of the hydroxycarboxylic acid receptor family. These G-protein coupled receptors (GPCRs) are central to the regulation of lipid metabolism and have emerged as critical targets for metabolic disorder research. Acifran’s high affinity and specificity for these receptors enable researchers to finely modulate lipid signaling pathways, making it a valuable hypolipidemic agent for lipid metabolism research and studies into lipid-related diseases.
The importance of selective GPCR agonists like Acifran has been underscored by recent structural biology advances. Notably, a landmark study by Ye et al. (2025, PLOS Biology) resolved cryo-EM structures of HCAR3 and HCAR2 in complex with Acifran, elucidating the molecular underpinnings of ligand recognition and selectivity. These insights directly inform experimental design and interpretation in lipid signaling research, offering a robust foundation for translational studies.
Step-by-Step Workflow: Deploying Acifran in Experimental Assays
1. Preparation and Handling
- Storage: Maintain Acifran at -20°C for maximum stability. Shipments from APExBIO are delivered with blue ice to preserve product integrity.
- Solubilization: Acifran is an off-white solid with a molecular weight of 218.21 g/mol and should be dissolved in DMSO or ethanol. Its solubility is less than 21.82 mg/ml in these solvents; prepare concentrated stocks accordingly (e.g., 10 mM in DMSO) and dilute into assay buffer immediately before use.
- Fresh Solution Use: For optimal agonist activity, prepare working solutions fresh before each experiment. Avoid long-term storage of dissolved Acifran, as recommended by APExBIO.
2. In Vitro Lipid Signaling Assays
- Cell Line Selection: Use HEK-293 or Sf9 cells stably expressing HM74A/GPR109A or GPR109B. These lines are validated for GPCR signaling studies and were employed in the structural study by Ye et al.
- Treatment: Add Acifran at concentrations ranging from 10 nM to 10 μM, titrating as needed for receptor occupancy and pathway activation. For cAMP inhibition assays, 1 μM Acifran consistently yields robust signal-to-noise ratios (see Acifran (SKU B6848): Data-Driven Solutions).
- Readout: Employ cAMP ELISA, BRET-based signaling readouts, or high-content imaging for downstream analysis. Integrate time-course studies to track rapid GPCR-mediated events (e.g., 0–60 min post-treatment).
3. Lipidomics and Downstream Analysis
- Following receptor activation, extract cellular lipids and analyze via LC-MS/MS to quantify changes in lipid metabolites, supporting direct correlations between Acifran treatment and metabolic pathway modulation.
- Integrate gene expression analysis (qPCR or RNA-seq) to assess transcriptional changes in lipid metabolism genes.
Advanced Applications and Comparative Advantages
Acifran’s validated selectivity profile makes it uniquely suited for dissecting the roles of HM74A/GPR109A versus GPR109B in lipid metabolism regulation. As detailed in Acifran: A Selective GPR109A/B Agonist, this compound’s ability to differentially activate these receptors allows researchers to model metabolic disorders such as dyslipidemia with unprecedented precision.
Recent breakthroughs in structural biology have further enhanced the utility of Acifran. The cryo-EM study by Ye et al. resolved the Acifran-HCAR3-Gi complex at 3.18 Å and the Acifran-HCAR2-Gi complex at 2.72 Å, providing atomistic detail on ligand–receptor interactions. These structures revealed that Acifran’s selectivity is driven by π–π interactions with residue F1073.32 and subtle differences in binding pocket volume, offering a rational basis for designing next-generation metabolic disorder research compounds.
Compared to traditional niacin-based HM74A/GPR109A agonists, Acifran offers a cleaner pharmacological profile, minimizing off-target effects and cutaneous flushing—a limitation of HCAR2 activation. This was further explored in Unlocking the Next Frontier in Lipid Metabolism Research, which contrasted Acifran’s precise activity with older, less selective agents, highlighting its advantages for translational and therapeutic research.
Additionally, in Acifran as a Structural Probe, the compound’s role as a tool for GPCR structural elucidation is emphasized, providing insights that extend beyond basic pharmacology to inform drug development pipelines.
Troubleshooting and Optimization Tips
- Solubility Issues: If precipitation occurs, gently warm the Acifran stock solution to 37°C and vortex. For cell-based assays, ensure final DMSO concentrations do not exceed 0.1% to avoid cytotoxicity.
- Assay Sensitivity: Titrate Acifran concentration in pilot assays to identify the EC50 for your system. Dose–response curves can reveal subtle differences in receptor expression or coupling efficiency.
- Reproducibility: Use freshly prepared solutions for each experiment. Batch-to-batch consistency is ensured by APExBIO’s >98% purity specification, but solution stability is time-limited.
- Negative Controls: Always include vehicle-only (DMSO/ethanol) and non-transfected cell controls to distinguish specific GPCR-mediated effects from background noise.
- Data Normalization: Normalize cAMP or lipidomic data to cell number or protein content to account for well-to-well variability.
For more troubleshooting scenarios and workflow optimization, Acifran (SKU B6848): Data-Driven Solutions provides a detailed account of common pitfalls and their resolution, highlighting the importance of quantitative validation in lipid metabolism research.
Future Outlook: Expanding the Impact of Acifran in Lipid-Related Disease Research
The high-resolution structural data generated by Ye et al. (2025) set the stage for rational drug design targeting HM74A/GPR109A and GPR109B. As a validated research tool, Acifran enables not only pathway dissection but also screening of candidate therapeutics with improved selectivity and reduced side-effect profiles, thus accelerating the translation of basic research into clinical applications.
Looking forward, integration of Acifran into multi-omics workflows—including transcriptomics, proteomics, and lipidomics—will provide a systems-level understanding of GPCR-mediated lipid metabolism regulation. The compound’s proven performance in both cellular and structural studies ensures that it will remain at the forefront of metabolic disorder research and drug discovery for years to come.
For researchers seeking a robust, high-purity G-protein coupled receptor agonist, Acifran from APExBIO stands as a gold-standard choice for lipid signaling pathway modulation and metabolic disease modeling. Explore more or order directly via the Acifran product page.